The NHLBI LAM Registry: Prognostic Physiologic and Radiologic Biomarkers Emerge From a 15-Year Prospective Longitudinal Analysis

• Published in: Chest Vol. 155; no. 2; pp. 288 - 296
• Main Authors: Gupta, Nishant, Lee, Hye-Seung, Ryu, Jay H, Taveira-DaSilva, Angelo M, Beck, Gerald J, Lee, Jar-Chi, McCarthy, Kevin, Finlay, Geraldine A, Brown, Kevin K, Ruoss, Stephen J, Avila, Nilo A, Moss, Joel, McCormack, Francis X
• Format: Journal Article
• Language: English
• Published: United States American College of Chest Physicians 01.02.2019
• Subjects: Age Factors; Biomarkers - analysis; Diffuse Lung Disease; Disease Progression; Female; Forced Expiratory Volume; Humans; Lipopolysaccharides - metabolism; Longitudinal Studies; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lung Neoplasms - surgery; Lymphangioleiomyomatosis - mortality; Lymphangioleiomyomatosis - pathology; Lymphangioleiomyomatosis - surgery; Menopause - physiology; National Heart, Lung, and Blood Institute (U.S.); Prognosis; Prospective Studies; Registries; Respiratory Function Tests; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis; Time Factors; Tomography, X-Ray Computed - methods; United States; United States; pulmonary function tests; VEGF-D; menopause; tuberous sclerosis complex; natural history
• ISSN: 1931-3543; 0012-3692; 1931-3543
• DOI: 10.1016/j.chest.2018.06.016

The natural history of lymphangioleiomyomatosis (LAM) is mainly derived from retrospective cohort analyses, and it remains incompletely understood. A National Institutes of Health LAM Registry was established to define the natural history and identify prognostic biomarkers that can help guide management and decision-making in patients with LAM. A linear mixed effects model was used to compute the rate of decline of FEV and to identify variables affecting FEV decline among 217 registry patients who enrolled from 1998 to 2001. Prognostic variables associated with progression to death/lung transplantation were identified by using a Cox proportional hazards model. Mean annual decline of FEV was 89 ± 53 mL/year and remained remarkably constant regardless of baseline lung function. FEV decline was more rapid in those with greater cyst profusion on CT scanning (P = .02) and in premenopausal subjects (118 mL/year) compared with postmenopausal subjects (74 mL/year) (P = .003). There were 26 deaths and 43 lung transplantations during the evaluation period. The estimated 5-, 10-, 15-, and 20-year transplant-free survival rates were 94%, 85%, 75%, and 64%, respectively. Postmenopausal status (hazard ratio, 0.30; P = .0002) and higher baseline FEV (hazard ratio, 0.97; P = .008) or diffusion capacity of lung for carbon monoxide (hazard ratio, 0.97; P = .001) were independently associated with a lower risk of progression to death or lung transplantation. The median transplant-free survival in patients with LAM is > 20 years. Menopausal status, as well as structural and physiologic markers of disease severity, significantly affect the rate of decline of FEV and progression to death or lung transplantation in LAM.